Bausch Health Companies (NYSE:BHC) Issues FY 2021 Earnings Guidance

Share on StockTwits

Bausch Health Companies (NYSE:BHC) updated its FY 2021 earnings guidance on Tuesday. The company provided earnings per share guidance of – for the period. The company issued revenue guidance of $8.60 billion-$8.80 billion, compared to the consensus revenue estimate of $8.66 billion.

Shares of BHC stock traded down $3.48 during trading hours on Tuesday, hitting $27.94. 10,284,975 shares of the company were exchanged, compared to its average volume of 4,614,434. The business has a 50 day moving average of $31.21 and a two-hundred day moving average of $25.54. The company has a market capitalization of $9.94 billion, a PE ratio of -5.13, a PEG ratio of 0.54 and a beta of 1.47. The company has a current ratio of 1.20, a quick ratio of 0.94 and a debt-to-equity ratio of 37.16. Bausch Health Companies has a 52 week low of $14.86 and a 52 week high of $34.80.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings data on Tuesday, February 23rd. The company reported $1.33 EPS for the quarter, topping the Zacks’ consensus estimate of $1.12 by $0.21. Bausch Health Companies had a negative net margin of 23.92% and a positive return on equity of 173.20%. The business had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.22 billion. On average, research analysts forecast that Bausch Health Companies will post 3.75 EPS for the current year.

BHC has been the topic of several research analyst reports. Citigroup upped their price objective on Bausch Health Companies from $32.00 to $37.00 in a research note on Tuesday, March 2nd. JPMorgan Chase & Co. reaffirmed a buy rating and set a $38.00 price target on shares of Bausch Health Companies in a report on Sunday, March 14th. Royal Bank of Canada raised Bausch Health Companies from a sector perform rating to an outperform rating and raised their price objective for the company from $26.00 to $42.00 in a research note on Wednesday, February 17th. Piper Sandler cut shares of Bausch Health Companies from an overweight rating to a neutral rating and boosted their target price for the stock from $25.00 to $30.00 in a research note on Friday, January 22nd. Finally, Bank of America reiterated an underperform rating and issued a $27.00 price target on shares of Bausch Health Companies in a research report on Tuesday, March 30th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of Hold and a consensus price target of $31.23.

About Bausch Health Companies

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

Further Reading: Real Estate Investment Trust (REIT) ETF

Earnings History and Estimates for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with's FREE daily email newsletter.